Optimal Value-Based TherapyVideo Categories: Polycythemia Vera
Supported through funding from Incyte
Drs. David Rimm and Roy Herbst review the problems with the CMS “14-Day Rule” since some of the multigene panel biomarker tests require 21 days or longer to complete.
Dr Morganna Freeman considers the future application of treatment modalities and how they might be combined for optimal results.